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Abstract
Background Fabry disease (FD) is an X-linked lysosomal storage disorder, caused by deficient activity of the alpha-galactosi-
dase A enzyme leading to progressive and multisystemic accumulation of globotriaosylceramide. Recent data point toward 
oxidative stress signalling which could play an important role in both pathophysiology and disease progression.
Methods We have examined oxidative stress biomarkers [Advanced Oxidation Protein Products (AOPP), Ferric Reducing 
Antioxidant Power (FRAP), thiolic groups] in blood samples from 60 patients and 77 healthy controls.
Results AOPP levels were higher in patients than in controls (p < 0.00001) and patients presented decreased levels of anti-
oxidant defences (FRAP and thiols) with respect to controls (p < 0.00001). In a small group of eight treatment-naïve subjects 
with FD-related mutations, we found altered levels of oxidative stress parameters and incipient signs of organ damage despite 
normal lyso-Gb3 levels.
Conclusions Oxidative stress occurs in FD in both treated and naïve patients, highlighting the need of further research in 
oxidative stress-targeted therapies. Furthermore, we found that oxidative stress biomarkers may represent early markers of 
disease in treatment-naïve patients with a potential role in helping interpretation of FD-related mutations and time to treat-
ment decision.
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Introduction
Fabry disease (FD) is an X-linked lysosomal storage disor-
der, caused by deficient activity of the alpha-galactosidase 
A enzyme (GAL-A), encoded by the GLA gene. The enzyme 
deficiency causes accumulation of the sphingolipid globo-
triaosylceramide (GL-3 or Gb3) and its deacylated deriva-
tive lyso-globotriaosylceramide (lyso-GL-3 or lyso-Gb3) in 
various cell types, in particular the vascular endothelial and 
the smooth muscle cells, cardiac myocytes, dorsal root gan-
glion neurons, neurons of the autonomic nervous system, 
brain and all types of kidney cells [1].
Although male patients are traditionally considered to 
develop a more severe phenotype than females, the disor-
der has a substantial clinical heterogeneity. The classical 
phenotype (type 1) exhibits early manifestations, whereas 
non-classical or late-onset phenotype (type 2) presents 
with clinical signs later in life [1]. In a multicentre study 
[2], classical FD was differentiated from non-classical FD 
by the presence of at least one of three clinical criteria 
 * Michelangelo Mancuso 
 michelangelo.mancuso@unipi.it
1 Department of Clinical and Experimental Medicine, 
Neurological Institute, University of Pisa, Pisa, Italy
2 Internal Medicine and Stroke Care Ward, Department 
of Promoting Health, Maternal-Infant, Excellence 
and Internal and Specialized Medicine (Promise) 
G. D’Alessandro, University of Palermo, Palermo, Italy
3 Regional Epilepsy Centre, Great Metropolitan Hospital “Bian
chi-Melacrino-Morelli”, Reggio Calabria, Italy
4 Lab Functional Genomics, Department of Biotechnology, 
Univ Verona, Genartis srl, Verona, Italy
5 Medical Genetics Unit, ASL 9, Verona, Italy
6 Internal Medicine Unit, Azienda Ospedaliera Universitaria 
Integrata di Verona, Verona, Italy
7 Department of Medical and Surgical Sciences, Pediatric Unit, 
“Magna Graecia” University, Catanzaro, Italy
8 Azienda Unità Sanitaria Locale, IRCCS di Reggio Emilia, 
Reggio Emilia, Italy
 Journal of Neurology
1 3
(neuropathic pain, angiokeratoma, and cornea verticillata) 
and an additional biochemical criterion in males (leukocyte 
GAL-A activity < 5%). Although several mutations in GLA 
have been associated to classic or late-onset forms, a defi-
nite genotype–phenotype correlation is not demonstrated, 
and diagnosis and classification should not be made only 
on genetic-basis.
Substrates deposition is related to tissue damage in FD; 
however, the underlying molecular mechanisms remain not 
completely understood. Recent data highlighted the role of 
oxidative stress in FD pathophysiology. FD patients present 
high lipid and protein oxidative damage, decreased antioxi-
dant defences and increased inflammatory biomarkers and 
cytokines [3–10]. Excess intracellular Gb3 induces oxidative 
stress and up-regulates the expression of cellular adhesion 
molecules in vascular endothelial cells [5]. Moreover, it has 
been suggested that pro-oxidant state occurs, is correlated 
and seems to be induced by Gb3 in Fabry patients [9].
Hypothesis/study objective/purpose
The aim of our multicentre project was to evaluate the role of 
oxidative stress in FD. In particular, we have evaluated (i) if 
oxidative stress occurs in blood; (ii) if there is an association 
between oxidative stress biomarkers and FD clinical mani-
festations and\or a difference between classic and late onset 
FD; (iii) if oxidative stress parameters over time are related 
with Lyso-Gb3 and disease appearance or progression, in 
a subgroup of eight treatment-naïve subjects/patients with 
normal Lyso-Gb3 levels, in order to see if selected oxidative 
stress biomarkers could represent early markers of disease 
progression.
Materials and methods
The patients group consisted of 60 Caucasian genetically 
proven FD subjects (Table 1) from Italy recruited from seven 
Italian centres with expertise in FD. Diagnosis and pheno-
type classification was performed according to international 
recommendations [1, 2], although few cases remained of 
uncertain interpretation as discussed below.
All the subjects had 10 ml of blood drawn from an ante-
cubital vein in the morning (at fast) for analysis of the 
advanced oxidation protein products (AOPP), antioxidant 
ferric-reducing power (FRAP), and total thiol groups.
The results were compared to those obtained from a pop-
ulation of 77 healthy controls (32 men, mean age 61.5 ± 18.2 
years), unrelated to the patients, who represent the normative 
values at the coordinator centre.
AOPP, a marker of oxidative damage to proteins, were 
assessed according to Witko-Sarsat et al. [11].
AOPP are well-known biomarkers used to evaluate the 
oxidative modification of proteins, which occurs through 
myeloperoxidase (MPO) activity of neutrophils. MPO 
catalyses the production of hypochlorous acid from hydro-
gen peroxide and chloride ions; hypochlorous acid is capa-
ble of oxidizing plasma proteins to generate AOPP. AOPP 
levels correlated with plasma concentrations of dityrosine 
and advanced glycation end-products (AGE)-pentosidine as 
indices of oxygen-mediated protein damage. AOPP measure 
highly oxidized proteins, especially albumin, and reflect the 
protein oxidation derived from neutrophils and monocytes 
[12]. Moreover, it appears that AOPP are integral part of the 
non-enzymatic antioxidant system of plasma proteome. Oxi-
dized fibrinogen, a molecule responsible for the positivity 
of AOPP chemical reaction, is bound to apolipoprotein(a), 
which could compete with plasminogen for its binding sites 
on fibrinogen, causing inhibition of fibrinolysis and promot-
ing cardiovascular damage. Though it is suggested that the 
AOPP system functions as a double-edged weapon of the 
plasma proteome, it by no means diminishes its diagnostic 
value as an oxidative stress biomarker [13]. For this reason 
and considering that oxidative modification products of pro-
teins have several advantages such as early formation, longer 
lifespan, greater stability and reliability in comparison with 
other oxidative markers [13], we have chosen AOPP as bio-
marker to test if protein-oxidative changes occur in FD.
In order to measure non-enzymatic anti-oxidant proper-
ties, FRAP was assessed in plasma samples, according to 
Benzie and Strain [14]. FRAP reflects the concentration 
of low molecular-weight non-enzymatic antioxidants and 
is independent of the concentration of proteins [15]. We 
selected FRAP assay for this study because it gives fast and 
reproducible results, permitting, at the same time, a more 
objective evaluation of the non-protein antioxidant activity.
The content of plasmatic total thiols (t-SH) was estimated 
by evaluation of the sulfhydryl groups present in the mol-
ecules, following the protocol described by Hu [16]. Sulf-
hydryl groups (-SH) are responsible for maintaining the 
structure and function of proteins, enzymes and membranes 
as well as they can decrease the damage caused by oxida-
tive stress.
Finally, lyso-Gb3 was analysed on dried blood spot (DBS) 
on different laboratories and data acquired at the coordinator 
centre for analysis.
We did not perform any statistical analysis between 
AGAL-A activity in peripheral blood leukocytes and oxi-
dative stress parameters because in our cohort most of the 
cases are female (66%), and in female AGAL-A activity is 
not a reliable marker of disease [1].
In a subgroup of eight patients in whom the diagnosis 
of FD was made being relatives of symptomatic cases, we 
have monitored oxidative stress biomarkers, Lyso-Gb3 
and eventual pre-clinical organ involvement over time. 
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Table 1  demographic, molecular and clinical features of the FD patients enrolled in the study
Gender Mutation Age of 
onset 
(years)
Clinical onset Clinical involvement at last follow-up
1 F c.337T > C p.Phe113Leu 33 – –
2 F c.337T > C p.Phe113Leu 27 – –
3 M c.337T > C p.Phe113Leu 62 Myocardial infarction HCM, Arrhythmia, Myocardial infarction
4 M deletion exons 3, 4 9 Acroparesthesia Acroparesthesia, HCM
5 M c.337T > C p.Phe113Leu 62 Arrhythmia Arrhythmia, HCM, Proteinuria, VBD
6 F deletion exons 3, 4 50 Acroparesthesia Acroparesthesia
7 M c.818T > C p.Phe273Ser 22 Acroparesthesia Acroparesthesia, HCM, Arrhythmia, Pro-
teinuria, Stroke, VBD
8 F c.337 T > C p.Phe113Leu 40 Stroke Stroke, Proteinuria
9 F c.550T > A 39 HCM HCM, Stroke
10 F IVS2-76_80 del15; IVS 4-16 A > G; IVS 6-22 
G > T
30 Acroparesthesia Acroparesthesia, Stroke
11 F .-10 G > T, IVS 6-22 C > T; IVS 6-51_54 
del14, g.9151 C > T
32 Acroparesthesia Acroparesthesia, Proteinuria, Stroke, GI 
disorders
12 M .-10 C > T; IVS 2-76_80 del 5; IVS 4-16 
A > G; IVS 6-22 C > T
4 GI disorders GI disorders, Acroparesthesia
13 F .- 30 G > A 30 Acroparesthesia Acroparesthesia, Stroke, GI disorders
14 F .-10 C > T; IVS 2-76_80 del 5; IVS 4-16 
A > G; IVS 6-22 C > T
35 Stroke Stroke, Acroparesthesia
15 F c.547 G > A p.G183S 17 Acroparesthesia Acroparesthesia, Proteinuria
16 M c.614delC 29 HCM HCM, Acroparesthesia
17 F c.614delC 12 Acroparesthesia Acroparesthesia, Stroke, HCM
18 F .-10 C > T; IVS 2-76_80 del 5; IVS 4-16 
A > G; IVS 6-22 C > T
30 Acroparesthesia Acroparesthesia
19 M .-10 C > T; IVS 2-76_80 del 5; IVS 4-16 
A > G; IVS 6-22 C > T
10 GI disorders GI disorders, Acroparesthesia, Proteinuria
20 F c.547 G > A p.G183S 22 – –
21 M c.337 T > C p.Phe113Leu 40 Proteinuria Proteinuria, HCM
22 F c.1146C > A; p.C382X 12 Proteinuria Proteinuria
23 F p.Tyr222Asp 49 Proteinuria Proteinuria, Arrhythmia, GI disorders
24 M c.640-859C > T 32 HCM HCM, Arrhythmia, Proteinuria, VBD, GI 
disorders
25 F D313Y 31 VBD VBD, GI disorders
26 F p.Ala377Asp 32 Acroparesthesia Acroparesthesia, Arrhythmia, Proteinuria
27 F c.1146C > A; p.C382X 30 Acroparesthesia Acroparesthesia, TIA, VBD, GI disorders
28 F c.640-859C > T 52 Proteinuria Proteinuria, HCM, Arrhythmia, VBD
29 F p.Tyr222Asp 13 Acroparesthesia Acroparesthesia, VBD, GI disorders
30 F D313Y 36 cSVD cSVD, VBD, Proteinuria
31 F p.Ala143Thr
p.Leu394Pro
41 – –
32 F p.Ala143Thr
p.Leu394Pro
41 Stroke Stroke
33 M c.818T > C p.Phe273Ser 62 HCM HCM, Arrhythmia, Proteinuria, cSVD, GI 
disorders
34 M N215S 64 HCM HCM, Arrhythmia
35 F c.334C > T p.Arg112Cys 62 Proteinuria Proteinuria, HCM, Arrhythmia, cSVD, VBD
36 F c.334C > T p.Arg112Cys 70 Arrhythmia Arrhythmia, HCM, cSVD, VBD
37 M c.334C > T p.Arg112Cys 37 Proteinuria Proteinuria, HCM, cSVD, VBD, Acropares-
thesia
38 F c.334C > T p.Arg112Cys 33 Acroparesthesia Acroparesthesia
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During this observational time, no additional therapies 
were undertaken, lifestyle did not change, and no unre-
lated FD diseases occurred.
The Ethic Committees of each centre approved the 
study, and patients provided informed consent to partici-
pate in this study.
Statistical analysis
Statistical analysis was performed using SPSS Statistics 
(Statistical Package for Social Science, 20.0 version for 
Windows). Quantitative data were given as mean ± SD. 
Normal distribution was determined using Kolmogo-
rov–Smirnov test. For comparisons between two groups, 
Student’s t test and Mann–Whitney U test were used as 
appropriate. Spearman correlation test was performed 
between the variables. p value < 0.05 was considered sta-
tistically significant.
Results
Table 1 shows the demographic, molecular and clinical 
features of the patients. We have enrolled 60 Italian geneti-
cally proven FD subjects (20 men, mean age 46.3 ± 17.3 
years, mean disease duration 14.9 years). For the sake of 
completeness, cases numbers 25 and 30, harbouring the 
D313Y mutation, and cases 40, 41 (Arg118Cys) remained 
of no obvious interpretation. In these cases, an extensive 
work up for other disease explaining organ damage was 
negative (including NGS screening for genes involved in 
hypertrophic cardiomyopathy (HCM) in cases 41). Fam-
ily history of cases 40 and 41 was also positive for renal 
failure and heart diseases in previous generations.
None of the enrolled patients was smoker or heavy 
drinker, and no additional diseases were reported. In eight 
cases (numbers 1, 2, 19, 30, 31, 32, 40, 41 Table 1), at the 
time of the genetic confirmation, multi organ screening 
Table 1  (continued)
Gender Mutation Age of 
onset 
(years)
Clinical onset Clinical involvement at last follow-up
39 M p.Cys63Tyr 46 Acroparesthesia Acroparesthesia, HCM, Arrhythmia, CKD, 
Stroke
40 F p.Arg118Cys 49 – –
41 M p.Arg118Cys 18 HCM HCM
42 F c.97G > T p.Asp33Tyr 51 GI disorders GI disorders, HCM
43 M c.851T > C p.Met284Thr 34 Proteinuria Proteinuria, HCM, Arrhythmia, CKD
44 F c.113delG 6 Acroparesthesia Acroparesthesia, Proteinuria, TIA
45 F c.113delG 8 GI disorders GI disorders, Proteinuria, Acroparesthesia
46 F c.335G > A Arg112His 22 Proteinuria Proteinuria
47 F c.860G > A 8 Acroparesthesia Acroparesthesia, HCM, Proteinuria, GI 
disorders
48 F c.860G > A 49 GI disorders GI disorders, HCM, Proteinuria
49 F c.779G > A 56 Proteinuria Proteinuria, HCM
50 F c. 846_847delTC 18 Proteinuria Proteinuria
51 M c. 846_847delTC 17 Proteinuria Proteinuria, HCM
52 F c. 846_847delTC 15 Proteinuria Proteinuria, PM, TIA
53 M C172Y 12 GI disorders GI disorders, Proteinuria
54 F C172Y 20 Proteinuria Proteinuria, HCM
55 M C172Y 23 Proteinuria Proteinuria
56 M c. 846_847delTC 62 Proteinuria Proteinuria
57 M C172Y 14 GI disorders GI disorders, HCM, Proteinuria
58 F c. 846_847delTC 25 Stroke Stroke, HCM, PM, Proteinuria, TIA
59 F c. 846_847delTC 12 Acroparesthesia Acroparesthesia, Proteinuria
60 F C172Y 5 – –
HCM hypertrophic cardiomyopathy, cSVD cerebral small vessel disease, VBD vertebrobasilar dolichoectasia, CKD chronic kidney disease, PM 
PaceMaker, GI gastrointestinal
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was either negative or revealed a sub-clinical organ 
impairment.
Hypertrophic cardiomyopathy and arrhythmia were sig-
nificantly more frequent in male (p = 0.002 and p = 0.043 
respectively) (Table 2). Age of stroke onset was earlier in 
females than males (37.73 years vs 43.5 years, p = 0.046), 
whereas gastrointestinal involvement was earlier in males 
(10 years) than in females (27.43 years, p = 0.02) (Table 3).
Table 4 presents values of oxidative stress parameters 
among patients and controls. As expected, the average val-
ues of all oxidative stress parameters in healthy controls 
were in the normal range, while AOPP levels were signifi-
cantly higher (p < 0.00001, Fig. 1) and FRAP (Fig. 2) and 
thiols (Fig. 3) significantly lower in FD than healthy controls 
(p < 0.00001). These parameters were not significantly dif-
ferent neither between enzyme replacement therapy (ERT) 
or non-ERT patients (AOPP: p = 0.129, FRAP p = 0.441, 
thiols p = 0.315) or gender (p = 0.799 for AOPP, p = 0.901 
for FRAP, p = 0.367 for thiols respectively), or age of onset 
of the disease.
No association was observed between hypertrophic car-
diomyopathy, arrhythmia, myocardial ischemia, proteinuria, 
renal failure, acroparesthesia, vertebrobasilar dolichoectasia, 
gastrointestinal involvement and oxidative stress parameters. 
The only observed association was between FRAP levels and 
stroke (p = 0.02), with pathologic levels of FRAP inversely 
associated with stroke.
No correlation between oxidative stress parameters and 
overall time of FD was found (AOPP p = 0.324; FRAP 
p = 0.192; thiols p = 0.581). Moreover, no correlation was 
observed between Lyso-Gb3 levels and AOPP (p = 0.415), 
FRAP (p = 0.51) or thiols (p = 0.827).
Comparing the classical (onset under 50 years of onset) 
and late onset FD forms, significant higher values of AOPP 
levels were observed in the late onset form (p = 0.04, 
Table 5). The same was observed in our control group (< 50 
years old vs > 50 years old, Table 6). Comparing late FD 
forms with the control subgroup over 50 years, a significant 
difference in the average values of AOPP, FRAP and thiols 
was found, as shown in Table 7.
Given the difference on age described above, we per-
formed a bivariate analysis, including age, and disease over-
all time (defined as difference between actual age and age at 
first disease manifestation) and cardiomyopathy as independ-
ent variables; the difference was significant despite correc-
tion for age (p = 0.047) and disease overall time (p = 0.045).
Figure 4 shows oxidative stress parameters over time in 
a subgroup of eight treatment-naïve patients all with nor-
mal Lyso-Gb3 (reference values < 1.8 ng/mL) at the enrol-
ment time, at the follow up and the relation with signifi-
cant clinical or subclinical events. Four patients (4A, B, C 
and D) showed a significant alteration in oxidative stress 
Table 2  Differences among sex in clinical features of FD
M male, F female, P p value
Bold values indicate statistically significant
Gender
M F p
Hypertrophic cardiomyopathy 14 (70%) 11 (28.2%) 0.002
Arrhythmia 8 (42.1%) 7 (17.5%) 0.043
Myocardial ischemia 1 (5.3%) 0.322
Proteinuria 14 (70%) 20 (50%) 0.141
Renal failure 2 (10%) 2 (5%) 0.595
Stroke 4 (20%) 15 (37.5%) 0.170
Acroparesthesia 7 (35%) 17 (43.6%) 0.525
Vertebrobasilar dolichoectasia 5 (25%) 7 (17.9%) 0.524
Gastrointestinal involvement 3 (15%) 10 (25.6%) 0.351
Table 3  Age of onset of different clinical features among FD gender
AGE OF ONSET years (standard deviation)
Male Female p
Hypertrophic cardiomyo-
pathy
44.36 (13.62) 52.38 (9.46) 0.17
Arrhythmia 55.71 (13.27) 58.67 (14.74) 0.762
Myocardial ischemia 62 (Only one case)
Proteinuria 41.67 (15.33) 39.13 (14.81) 0.693
Renal failure 47 Only one case
Stroke 43.5 (0.71) 37.73 (3.49) 0.046
Acroparesthesia 18.8 (11.78) 26.2 (13.79) 0.298
Vertebrobasilar dolich-
oectasia
49.5 (17.68) 49.25 (21.28) 0.989
Gastrointestinal involve-
ment
10 27.43 (17.51) 0.02
Table 4  Values of oxidative 
stress (AOPP, FRAP, Thiols) 
among patients and controls. 
RV: reference values. IQR: 
interquartile range
Bold values indicate statistically significant
Median Value (IQR) 
Patients
Median Value (IQR) 
Controls
P
AOPP (RV 124.5–190.5 nmol/mL) 342.74 (146.15) 185.32 (43.93) < 0.000001
FRAP (RV > 0.7 mmol/L) 0.61 (0.18) 0.78 (0.12) < 0.000001
Thiols (RV 0.4–0.6 mmol/L) 0.28 (0.10) 0.47 (0.12) < 0.000001
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parameters already before the appearance of organ impair-
ment or signs of FD features at the last follow up. Other two 
patients (4E and 4F) showed pathological oxidative stress 
parameters already before the appearance of organ damage, 
while Lyso-Gb3 remained normal. The last two cases (4G 
and 4H) showed pathological oxidative stress parameters 
and normal Lyso-Gb3 at the time of the diagnosis, having 
already presented impairment of one or more organ target.
Discussion
In this study, we observe a significant imbalance of the oxi-
dative stress status in FD patients in different disease stage, 
including those cases in which Lyso-Gb3 was normal and\
or organ damage was not yet manifested.
ERT has changed the natural history of the disease in 
FD patients. Initiation of ERT in childhood could slow, or 
even stop the progression of organ damage before irrevers-
ible changes occur [17]. Although the exact pathogenesis of 
FD is still under unclear, the accumulation of Gb3 and lyso-
Gb3 in vascular endothelia and subsequent inflammation is 
thought to play a crucial role, whereas early ERT initiation 
may reduce lyso-Gb3 deposition and mitigate disease pro-
gression [18]. ERT seems to be less effective in patients 
with both delayed diagnosis and initiation of ERT, and in 
classic FD there is a tendency to initiate therapy when early 
symptoms or signs of organ damage occurs [18]. Moreo-
ver, in a recent consensus recommendation paper [17] it has 
been suggested that asymptomatic boys may benefit from 
an earlier initiation of ERT based on the following crite-
ria: presence of a pathogenic GLA variant responsible for 
the classic phenotype, family history of disease severity in 
males, undetectable AGAL‐A activity in peripheral blood 
leukocytes and plasma lyso-Gb3 over 20 nmol/L. Therefore, 
biomarkers could be used as reliable features to guide the 
clinician in the therapeutic management.
Fig. 1  AOPP values in FD patients and controls
Fig. 2  FRAP values in FD patients and controls
Fig. 3  Thiols values in FD patients and controls
Table 5  Average values of oxidative stress parameters in classic vs 
late onset FD
Bold value indicates statistically significant
N Mean Standard Deviation p
AOPP
 Late 10 428.5900 187.40270 0.040
 Classic 48 324.8558 131.47583
FRAP
 Late 8 0.62338 0.139265 0.903
 Classic 46 0.61476 0.189121
Thiols
 Late 10 0.24570 0.079635 0.227
 Classic 48 0.29217 0.114189
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On the other hand, in recent years there are several evi-
dences that the accumulation of Lyso-Gb3 is not the only 
mechanism underlying the progression in FD. Several 
authors have put forward the hypothesis that oxidative 
stress has a key role in the progression of organ damage in 
FD. In 2012, Biancini and collaborators demonstrated that 
in FD pro-oxidant states occur and seem to be induced by 
Lyso-Gb3 [19]. In their study, decreased levels of antioxi-
dant defences (reduced glutathione, glutathione peroxidase 
activity and increased superoxide dismutase/catalase ratio in 
erythrocytes), and high levels of malondialdehyde (MDA) 
and protein carbonyl groups products (product of proteins 
and lipid damage) were observed [19]. Interestingly, urinary 
Gb3 levels were positively correlated with the plasma levels 
of IL-6, carbonyl groups and MDA, suggesting a possible 
link between lyso-GB3 and oxidative stress [19]. In 2016, 
we have also hypothesised that mitochondrial DNA haplo-
groups may be involved in modulating the oxidative stress 
in FD, thus explaining the heterogenous expression of FD 
phenotype [20].
In 2015, Chimenti et al. have evaluated the role of oxida-
tive stress in FD cardiomyocyte dysfunction; they found that 
GB3-induced myocardial ROS production provides a major 
contribution to cardiac dysfunction of FD cardiomyopathy 
[21].
Recently, Ravarotto et al. have documented oxidative 
stress activation and oxidative stress signalling (higher 
p22phox expression and MDA levels), suggesting a possi-
ble role of oxidative stress in cardiovascular-renal remodel-
ling pathophysiology [22]. In their work, patients were all in 
ERT, suggesting that oxidative stress occurs despite ERT in 
FD related-left ventricular hypertrophy. Similar conclusions 
were reached by Biancini et al. in 2016 that showed higher 
lipid peroxidation levels in FD before ERT, which could not 
be reversed by the treatment [7]. These findings have led 
to suppose a role for oxidative stress-targeted therapies in 
addition to ERT in FD.
It has been shown that Gb3 accumulation is not limited 
to the lysosomes but also in endothelial cells membranes, 
inducing deregulating endothelial NO synthase activity with 
reduced NO production that favours oxidative stress [23].
Our results confirm oxidative stress activation in FD; 
in particular, we have observed high levels of AOPP and 
reduced levels of antioxidants (FRAP and thiols) in patients 
compared to healthy controls; these parameters were altered 
despite ERT, confirming Biancini observation [7]. Given 
the others study on oxidative stress published up so far, we 
might assume a vicious cycle between Lyso-Gb3 deposi-
tion and oxidative stress: Lyso-Gb3 deposition induces organ 
damage, endothelial dysfunction, increases vascular super-
oxide and free radical formation, oxidative DNA damage 
and altered oxidative response, which in turn enhances organ 
damage and remodelling.
Table 6  Average values of 
oxidative stress parameters in 
healthy controls (< 50 ys old 
vs > 50 ys old)
Bold values indicate statistically significant
AGE N Mean Std. Deviation Std. Error Mean p
AOPP ≥ 50 58 195.7238 33.88970 4.44994 0.007
< 50 19 164.9105 61.68450 14.15139
FRAP ≥ 50 58 0.78448 0.133982 0.017593 0.014
< 50 19 0.69931 0.104409 0.023953
Thiols ≥ 50 58 0.48364 0.129588 0.017016 0.154
< 50 19 0.43768 0.086380 0.019817
Table 7  Average values of 
oxidative stress parameters 
in late onset FD vs healthy 
controls (> 50 years old)
Bold values indicate statistically significant
N Mean Std. Deviation Std. Error Mean p
AOPP
 Late Form 10 428.5900 187.40270 59.26194 < 0.000001
 Controls ≥ 50 58 195.7238 33.88970 4.44994
FRAP
 Late Form 8 0.62338 0.139265 0.049238 0.002309
 Controls ≥ 50 58 0.78448 0.133982 0.017593
Thiols
 Late Form 10 0.24570 0.079635 0.025183 < 0.000001
 Controls ≥ 50 58 0.48364 0.129588 0.017016
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Fig. 4  Oxidative stress param-
eters (blue: Thiols, orange: 
FRAP, red: AOPP) and Lyso-
Gb3 (yellow) values over time. 
The green area and dashed 
lines show reference values 
(RV) (AOPP < 190.5 nmol/
mL; Lyso-Gb3 < 1.8 ng/
mL; Thiols > 0,4 mmol/L; 
FRAP > 0.7 mmol/L). RV are 
obtained from a population of 
77 healthy controls (32 men, 
mean age 61.5 ± 18.2 years), 
unrelated to the patients, 
recruited at the coordinator 
centre. The vertical dashed line 
indicates the appearance of 
a clinical event related to FD 
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We have not observed an association between oxidative 
stress parameters alteration and disease manifestations. The 
inverse association between pathological values of FRAP 
and stroke (the opposite of what one would expect, given 
the possible role of oxidative stress in cerebral small vessels 
disease) is unclear and requires further investigation.
We also found significantly higher levels of AOPP 
between late onset and classic FD, despite correction for 
age and disease overall time.
Interestingly, in a group of eight treatment-naïve subjects/
patients with FD-related mutations and normal Lyso-Gb3 
levels we have found pathological oxidative stress parame-
ters. Lyso-Gb3 levels didn’t correlate with the evaluated bio-
markers; we can assume that these parameters reflect early 
activation of oxidative stress and organ damage, before lyso-
Gb3 elevation, but further studies are needed. This group 
consisted of some challenging cases: two pre-symptomatic 
young females with the pathogenic p.Phe113Leu, tradition-
ally related to a late-onset phenotype, in which lysoGB3 
levels could be sometimes normal [24]; a 10-year-old male 
with a classical phenotype and normal levels of LysoGB3; 
two females with the recently considered “likely benign” 
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variant D313Y but manifesting some clinical manifesta-
tions of FD [25, 26]; a 18-year-old male with HCM, and 
his asymptomatic mother, with the Arg118Cys variant with 
conflicting interpretations of pathogenicity according to 
ClinVar [27–29]. These cases rise some queries about the 
diagnostic value of lyso-GB3 in some settings, and confirms 
that diagnosis of FD cannot be made solely on genetic basis. 
Histopathologic studies are crucial in challenging cases to 
confirm the diagnosis of FD but may be invasive (as in myo-
cardial biopsy), and not always available in some settings. 
Unfortunately, we do not have histopathological studies 
in our cases. The altered parameters of oxidative stress in 
the above cases may suggest an early involvement of redox 
imbalance in FD-induced organ damage, disease onset and 
progression. Although some authors have demonstrated the 
progression of organ damage in ERT patients, the early treat-
ment is considered to be the key to dramatically change the 
natural history of disease in these patients [18, 30, 31]. Our 
results are not enough to state that ERT should be started in 
subjects with FD-related mutations who do not have signs or 
symptoms of disease but signs of oxidative stress, however 
they pave the way for further studies. To date, beside AGAL-
A activity in males, the only surrogate biomarker recognized 
in FD is Lyso-Gb3. Considering what we have observed, 
specific oxidative stress markers could be even more sensi-
tive than Lyso-Gb3 in the early phase of the disease, thus 
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representing new early biomarkers with a potential role in 
helping diagnosis and time to treatment decision.
Our study has some limitations. We have enrolled patients 
at different stage of disease, and the timing of the biomarkers 
analysis was variable from patient to patient. Moreover, most 
of our cases are females, thus we could not correlate AGAL-
A activity with the other findings. No complete data about 
all possible comorbidities were available, although patients 
didn’t have significant comorbidities such as cancer or other 
inflammatory disorders.
In conclusion, oxidative stress occurs in FD in both 
treated and naïve patients, highlighting the need of further 
collaborative research in oxidative stress-targeted therapies 
in addition to ERT in order to further slow disease progres-
sion. Furthermore, oxidative stress biomarkers may repre-
sent early markers of disease in treatment-naïve patients with 
a potential role in helping interpretation of FD-related muta-
tions and time to treatment decision.
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